# US 2025/0145571 A1 · Amino acid prodrugs of nicorandil

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145571 A1
- Document ID: US20250145571A1
- Status: Published application
- Kind: A1
- Application number: 18/898,468
- Filed: 2024-09-26
- Published: 2025-05-08
- Earliest claimed: 2023-09-26
- Assignees: Unicycive Therapeutics, Inc.
- Applicants: Unicycive Therapeutics, Inc.
- Inventors: Roopa RAI
- Web page: https://patentgrep.com/patent/US20250145571A1

## CPC

- C07D 213/82: in position 3
- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/465: Nicotine; Derivatives thereof
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07D 213/44: Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to nicorandil derivative compounds, pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions for treating diseases or conditions.

## Claims

### Claim 1

A compound according to formula (I):
or a stereoisomer thereof;
wherein X− indicates one or more counter ions;
Y is H or C1-C4 alkyl;
R is selected from
R1 is H or C1-C4 alkyl;
R2 is H or C1-C4 alkyl;
R3 is H or unsubstituted or substituted C1-C4 alkyl; or R1 and R3 are joined together to form a 4-7 membered substituted or unsubstituted heterocycloalkyl;
R4 is H or C1-C8 alkyl;
R5 and R6 are independently selected from hydrogen, C1-C8 alkyl, a 6-10 membered substituted or unsubstituted aryl, and a 6-10 membered substituted or unsubstituted heteroaryl;
R7 is H or C1-C12 alkyl;
X1 and X2 are independently selected from NH, O, and S; and
is a single or double bond;
wherein when Y is H, R7 is not —CH(CH3)2, —CH2CH(CH3)2, —C(CH3)3, or —CH2C(CH3)3.

### Claim 2 (depends on 1)

The compound of claim 1, according to Formula (I-1):
or a stereoisomer thereof.

### Claim 3 (depends on 2)

The compound of claim 2, according to Formula I-1a:
or a stereoisomer thereof.

### Claim 4 (depends on 2)

The compound of claim 2, according to Formula I-1b:
or a stereoisomer thereof.

### Claim 5 (depends on 1)

The compound of claim 1, according to Formula (I-2):
or a stereoisomer thereof.

### Claim 6 (depends on 5)

The compound of claim 5, according to Formula (I-2a):
or a stereoisomer thereof.

### Claim 7 (depends on 5)

The compound of claim 5, according to Formula (I-2b):
or a stereoisomer thereof.

### Claim 8 (depends on 1)

The compound of claim 1, wherein:
R3 is H or unsubstituted or substituted C1-C4 alkyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R3 is substituted C1-C4 alkyl and the substitutions are selected from hydroxyl, heteroalkyl, aryl, heteroaryl, —COOH, —CONH2, and —NH2.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R3 is selected from H, —CH3, —(CH2)3—NH—C(NH2)═NH, —CH2—CONH2, —CH2—COOH, —CH2—SH, —(CH2)2—CONH2, —(CH2)2—COOH, —CH2-1H-imidazole, —CH(CH3)CH2—CH3, —CH2—CH—(CH3)2, —(CH2)4—NH2,
—(CH2)2—S—CH3, —CH2-Ph, —CH2—OH, —CH(OH)—CH3, —CH2-1H-indole, —CH2-Ph-OH, and —CH—(CH3)2.

### Claim 11 (depends on 10)

The compound of claim 10, wherein R3 is selected from —CH3, —CH2—OH, —CH2-Ph, —CH2—CONH2, and CH2—C(H)—(CH3)2.

### Claim 12 (depends on 2)

The compound of claim 2, wherein R3 is selected from —CH3, —CH2—OH, —CH2-Ph, —CH2—CONH2, and CH2—C(H)—(CH3)2.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R1 and R3 are joined together to form a pyrrolidine ring.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R5 is a 6-10 membered substituted or unsubstituted aryl.

### Claim 16 (depends on 1)

The compound of claim 1, wherein R2 is H.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R4 is H.

### Claim 18 (depends on 1)

The compound of claim 1, wherein R4 is C1-C8 alkyl.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R4 is H, —CH3, —CH2—CH3, or —CH(CH3)2.

### Claim 20 (depends on 1)

The compound of claim 1, of Formula (I-3):
or a stereoisomer thereof.

### Claim 21 (depends on 20)

The compound of claim 20, wherein R5 and R6 are independently selected from hydrogen and C1-C8 alkyl.

### Claim 22 (depends on 1)

The compound of claim 1, according to Formula (I-4):
or a stereoisomer thereof.

### Claim 23 (depends on 22)

The compound of claim 22, wherein R7 is C1-C12 alkyl.

### Claim 24 (depends on 22)

The compound of claim 22, wherein R7 is C1-C2 alkyl.

### Claim 25 (depends on 22)

The compound of claim 22, wherein R7 is C6-C12 alkyl.

### Claim 26 (depends on 1)

The compound of claim 1, according to Formula (I-5):
or a stereoisomer thereof.

### Claim 27 (depends on 26)

The compound of claim 26, wherein X1 and X2 are both H.

### Claim 28 (depends on 26)

The compound of claim 26, wherein R1 is C1-C4 alkyl.

### Claim 29 (depends on 1)

The compound of claim 1, wherein Y is H.

### Claim 30 (depends on 2)

The compound of claim 2, of the formula:
or a stereoisomer thereof.

### Claim 31 (depends on 1)

The compound of claim 1, selected from

### Claim 32 (depends on 1)

The compound of claim 1 selected from:
or a stereoisomer thereof.

### Claim 33 (depends on 1)

The compound of claim 1, selected from the group consisting of:

### Claim 34 (depends on 33)

The compound of claim 33, of the formula:

### Claim 35 (depends on 1)

The compound of claim 1, selected from the group consisting of:

### Claim 36 (depends on 1)

The compound of claim 1, wherein X− is selected from F−, Cl−, Br−, I−, MeSO2O−, acetate, carbonate, chromate, citrate, fumarate, lactate, malonate, nitrate, phosphate, tartrate, trifluoroacetate, succinate, formate and sulfate.

### Claim 37 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutically acceptable carriers, excipients, or diluents.

### Claim 38 (depends on 1)

A method for treating a disease or a condition comprising the step of administering an effective amount of the compound of claim 1 or a pharmaceutical composition thereof to a subject in need thereof.

### Claim 39 (depends on 38)

The method of claim 38, wherein the disease or condition is acute kidney disease, chronic kidney disease, diabetic nephropathy, IgA nephropathy, acute kidney failure, acute tubular necrosis, transplant related ischemia, or acute kidney injury (AKI).

### Claim 40 (depends on 39)

The method of claim 39, wherein the AKI is drug-induced AKI.

### Claim 41 (depends on 40)

The method of claim 40, wherein the drug-induced AKI is chemotherapy-induced AKI or immunotherapy-induced AKI.

### Claim 42 (depends on 41)

The method of claim 41, wherein the AKI is cisplatin induced AKI, aminoglycosides induced AKI, tenofovir induced AKI, contrast induced nephropathy, or PD-1/PDL-1 inhibitor-induced AKI.

### Claim 43 (depends on 42)

The method of claim 42, wherein the PD-1/PDL-1 inhibitor-induced AKI is pembrolizumab (Keytruda)-induced AKI, durvalumab-induced AKI, atezolizumab-induced AKI, avelumab-induced AKI, nivolumab-induced AKI, durvalumab-induced AKI, cemiplimab-induced AKI, dostarlimab-induced AKI, and retifanlimab-induced AKI.

### Claim 44 (depends on 39)

The method of claim 39, wherein the AKI is AKI after surgery for partial nephrectomy, AKI post kidney transplant, AKI in patients with dialysis, AKI after cardiac surgery, AKI in patients inside ICU, or AKI caused by cirrhosis or sepsis and AKI caused by hepatorenal syndrome.

### Claim 45 (depends on 39)

The method of claim 39, wherein the disease or condition is acute kidney failure.

### Claim 46 (depends on 39)

The method of claim 39, wherein the disease or condition is chronic kidney disease.

### Claim 47

(canceled)

### Claim 48

(canceled)
